human growth hormone comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-30. Numbers and descriptions here follow the published literature rather than marketing material.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
But Edith said she had agreed to marry Field only because she felt "on the shelf" and had begun to doubt that Tolkien still cared for her. She explained that, because of Tolkien's letter, everything had changed. On 8 January 1913 Tolkien travelled by train to Cheltenham and was met on the platform by Edith. The two took a walk into the countryside, sat under a railway viaduct, and talked. By the end of the day, Edith had agreed to accept Tolkien's proposal. She wrote to Field and returned her engagement ring. Field was "dreadfully upset at first", and the Field family was "insulted and angry". Upon learning of Edith's new plans, Jessop wrote to her guardian, "I have nothing to say against Tolkien, he is a cultured gentleman, but his prospects are poor in the extreme, and when he will be in a position to marry I cannot imagine. Had he adopted a profession it would have been different." Following their engagement, Edith reluctantly announced that she was converting to Catholicism at Tolkien's insistence. Jessop, "like many others of his age and class ... strongly anti-Catholic", was infuriated, and he ordered Edith to find other lodgings. Edith Bratt and Ronald Tolkien were formally engaged at Birmingham in January 1913, and married at St Mary Immaculate Catholic Church at Warwick, on 22 March 1916. In a 1941 letter to Michael, Tolkien expressed admiration for his wife's willingness to marry a man with no job, little money, and no prospects except the likelihood of being killed in the Great War.
Leucotomy was first undertaken in 1935 under the direction of the Portuguese neurologist (and inventor of the term psychosurgery) António Egas Moniz. First developing an interest in psychiatric conditions and their somatic treatment in the early 1930s, Moniz conceived a new opportunity for recognition in the development of a surgical intervention on the brain as a treatment for mental illness.
Similar to water, graphite oxide easily incorporates other polar solvents, e.g. alcohols. However, intercalation of polar solvents occurs significantly different in Brodie and Hummers graphite oxides. Brodie graphite oxide is intercalated at ambient conditions by one monolayer of alcohols and several other solvents (e.g. dimethylformamide and acetone) when liquid solvent is available in excess. Separation of graphite oxide layers is proportional to the size of alcohol molecule. Cooling of Brodie graphite oxide immersed in excess of liquid methanol, ethanol, acetone and dimethylformamide results in step-like insertion of an additional solvent monolayer and lattice expansion. The phase transition detected by X-ray diffraction and differential scanning calorimetry (DSC) is reversible; de-insertion of solvent monolayer is observed when sample is heated back from low temperatures. An additional methanol and ethanol monolayer is reversibly inserted into the structure of Brodie graphite oxide under high pressure conditions. Hummers graphite oxide is intercalated with two methanol or ethanol monolayers at ambient temperature. The interlayer distance of Hummers graphite oxide in an excess of liquid alcohols increases gradually upon temperature decrease, reaching 19.4 and 20.6 Å at 140 K for methanol and ethanol, respectively. The gradual expansion of the Hummers graphite oxide lattice upon cooling corresponds to insertion of at least two additional solvent monolayers.
Sources: en.wikipedia.org
He stays on and on and on! He will be with me forever-because he has this President wrapped around his little finger". Not until August 1973 did Nixon inform Kissinger that he was sacking Rogers and appointing him as his successor. Thiệu's government was still receiving massive amounts of military aid, and his regime controlled 75% of South Vietnam's territory and 85% of the population at the time of the ceasefire. But Thiệu's unwillingness to crackdown on corruption and end the system under which ARVN officers were promoted for political loyalty instead of military merit were structural weaknesses that spelled long-term problems for his regime. South Vietnam's economy had been heavily dependent upon the hundreds of millions of dollars brought in by the U.S. military, and the withdrawal of American forces threw the economy into recession. Even more damaging was the Arab oil shock of 1973–74, which destabilized South Vietnam's economy, and by the summer of 1974, 90% of the ARVN's soldiers were not receiving enough pay to support themselves and their families.
The CBC measures the amounts of platelets and red and white blood cells, along with the hemoglobin and hematocrit values. Red blood cell indices—MCV, MCH and MCHC—which describe the size of red blood cells and their hemoglobin content, are reported along with the red blood cell distribution width (RDW), which measures the amount of variation in the sizes of red blood cells. A white blood cell differential, which enumerates the different types of white blood cells, may be performed, and a count of immature red blood cells (reticulocytes) is sometimes included.
Nalbuphine in the 15 to 60 mg range had similar analgesic effects to immediate release codeine in the 30 to 60 mg range (Kantor et al. 1984; Sunshine et al. 1983). Schmidt et al. (1985) reviewed the preclinical pharmacology of nalbuphine and reported comparative data relative to other types of opioid compounds. The authors point out that the nalbuphine moiety is approximately ten times more pharmacologically potent than the mixed opioid agonist/antagonist butorphanol on an "antagonist index" scale which quantitates the drug's ability to act both as an analgesic (via opioid KOR agonism) as well as a MOR antagonist. The opioid antagonist activity of nalbuphine is one-fourth as potent as nalorphine and 10 times that of pentazocine.
== Uses == The drug Prajmaline has been used to treat a number of cardiac disorders. These include: coronary artery disease, angina, paroxysmal tachycardia and Wolff–Parkinson–White syndrome. Prajmaline has been indicated in the treatment of certain disorders where other antiarrhythmic drugs were not effective.
Sources: en.wikipedia.org
=== Temperature Tuesday === In 2010, Runza introduced their Temperature Tuesdays promotion. In January and February, the coldest temperature at a Runza at 6AM would be the price of an original Runza sandwich with the purchase of medium french fries and a drink (ex. if the coldest temperature at a Runza was 11° at Ogallala, an original Runza would be 11¢ with purchase of a medium fry and drink). If the temperature was below zero, a Runza would be free with the purchase of a medium fry and drink. The promotion has since been shortened to only take place in January.
The three substrates of this enzyme are (R)-mevalonate, coenzyme A (CoA), and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are (S)-3-hydroxy-3-methylglutaryl-CoA, reduced NADPH, and two protons. This enzyme belongs to the family of oxidoreductases, to be specific those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. This enzyme participates in biosynthesis of steroids including cholesterol. The statin class of anticholesterol drugs act through inhibiting this enzyme.
During its development, Black Mesa received attention from several video game publications. It was featured in articles from Computer Gaming World, PC PowerPlay, and PC Gamer UK magazines. Valve published a news update about the modification on their Steam digital distribution platform in 2007, saying that "We're as eager to play [Black Mesa] here as everyone else." The project was awarded Top Unreleased Mod by video game modification website Mod DB in 2005 and 2006. Mod DB gave the project an honorable mention in their choice of Top Unreleased Mod in 2007. After receiving a development version of Black Mesa in December 2009, PC PowerPlay magazine said that the game's setting "looks, sounds, [and] plays better than ever before". The "subtle" changes from the original Half-Life were said to have a "substantial" overall impact. They also noted the project's "frustrating" then-five-year development time, and current lack of release date, but added that the developers were making progress. After the first major release in 2012, early impressions of the game were very positive, receiving a score of 86/100 on review aggregator Metacritic, based on nine reviews. The game was praised for its high polish, with many critics comparing its quality to that of an official Valve game. Destructoid praised the game for the improvements it made over the original Half-Life, saying it was "something that felt very familiar, [but also] very fresh." Black Mesa won ModDB's Mod of the Year Award for 2012.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.